Nasdaq Flags Nexentis for Missing Stockholders' Equity Minimum
NXTS sits 17% above its 52-week low of $1.43.
Summary
Nexentis received a Nasdaq deficiency notice for falling below the $2.5M minimum stockholders' equity requirement, with a compliance plan due by October 15, 2026.
Key Events · Legal and Risk Events · NXTS
-
Nasdaq Deficiency Notice Received
On August 31, 2026, Nasdaq notified Nexentis that stockholders' equity of $1,782,000 as of June 30, 2026 falls below the $2,500,000 minimum required under Listing Rule 5550(b)(1).
-
Compliance Plan Deadline
Nexentis must submit a plan to regain compliance by October 15, 2026. If accepted, Nasdaq may grant up to 180 days (through February 27, 2027) to evidence compliance.
-
Delisting Risk
If the plan is rejected or compliance is not regained, Nasdaq would issue a delisting determination. Nexentis could then request a hearing, which would stay any delisting action.
-
Distress Context
This deficiency follows a going-concern warning reiterated in the August 13, 2026 10-Q, a $6.3M goodwill impairment, and multiple deeply discounted offerings in June 2026.
Analysis · NXTS · Life Sciences
A Nasdaq deficiency letter landed on August 31, 2026, after Nexentis Technologies reported stockholders' equity of $1,782,000 in its Q2 10-Q — short of the $2,500,000 minimum required for continued listing. The company now has until October 15, 2026 to submit a compliance plan; if accepted, it could receive up to 180 days (through February 27, 2027) to regain compliance. This is the first public disclosure of the deficiency, and it arrives amid a series of distress signals: a going-concern warning reiterated in the August 13 10-Q, a $6.3M goodwill impairment, and multiple deeply discounted offerings in June. A delisting would severely impair liquidity and access to capital for a company already burning cash.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 44% of the 562 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.52%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NXTS was trading at $1.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4M. The 52-week trading range was $1.43 to $58.75. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.